KRYS

Krystal Biotech Inc.

Price

$343.34

return (12m)

138.50%

p/e

40.87

p/bv

7.26

DIVIDEND YIELD

0.00%

KRYS price

Krystal Biotech

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment KRYS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

1.94%

3 months

12.86%

1 year

138.50%

2 years

72.80%

5 years

544.17%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals KRYS

Valuation

P/E

40.87

Sector -4.38

Industry -4.38

P/BV

7.26

Sector 2.02

Industry 2.02

P/Revenue (PSR)

22.41

Sector -4.40

Industry -4.40

EV/EBITDA

150.45

Sector -263.09

Industry -263.09

EV/EBIT

154.46

Sector -702.90

Industry -702.90

P/EBITDA

48.28

Sector -4.39

Industry -4.39

P/EBIT

49.91

Sector -4.73

Industry -4.73

P/Total Assets

6.58

Sector 1.49

Industry 1.49

P/Net Current Assets

10.75

Sector -11.70

Industry -11.70

P/Working Capital

10.59

Sector -3.19

Industry -3.19

EPS

8.05

Sector -2.14

Industry -2.14

BVPS

45.30

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

94.64%

Sector 36.74%

Industry 36.74%

EBITDA Margin

50.31%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

49.00%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

44.89%

Sector -38.22%

Industry -38.22%

Net Profit Margins

54.82%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.08

Sector 0.03

Industry 0.03

Profitability

ROE

17.77%

Sector -65.14%

Industry -65.14%

ROA

16.09%

Sector -65.53%

Industry -65.53%

ROIC

38.59%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

8.32

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-14.10

Sector -6.07

Industry -6.07

Net Debt / EBIT

-14.48

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.62

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.91

Sector 0.41

Industry 0.41

Liabilities/Assets

0.09

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Krystal Biotech ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$343.34

Fair Value

$90.58

Upside Return potential.

-73.62%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals KRYS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
KRYS Krystal Biotech Inc.	$343.34	134.68%	0.00%	40.87	7.26	17.77%	54.82%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

KRYS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Krystal Biotech

Krystal Biotech Inc.

Average Investor10 user rating

4.0 (3 people)

United States

11 years

Founded: 2015

2017

Time since IPO - 9 years

75

Employees

Krystal Biotech Inc. (United States) is listed on the Nasdaq and has a market capitalization of $9.87 billion, with shareholders equity totaling $1.36 billion.

The company employs approximately 75 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Krystal Biotech Inc. reported $440.49 million in revenue, generating net income of $241.46 million.

Key financial metrics include a P/E ratio of 40.87, a price-to-book (P/B) ratio of 7.26, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker KRYS.

Market cap

$9.87 billion

Net worth

$1.36 billion

$1,359,130,000.00

Assets

$1.50 billion

$1,500,650,000.00

Total Shares Outstanding

30.00 million

30,000,000

Average Daily Trading Volume

$458.10 Thousand

$458,101.04

Sector

Health Care

Industry

Biotechnology

KRYS

KRYS revenue and profits

Financial Results KRYS

DRAG THE FRAME TO SEE MORE DATA

KRYS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Krystal Biotech (KRYS) today?

A cotação de Krystal Biotech (KRYS) hoje está em US$ 343.34, com uma variação de 138.5% em relação ao último ano. A cotação de Krystal Biotech (KRYS) iniciou o ano negociando na casa dos US$ 246.54 e hoje está em US$ 343.34. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Krystal Biotech (KRYS) e dados de ações do Ibovespa e mercados internacionais.

Quando Krystal Biotech (KRYS) paga dividendos?

Krystal Biotech (KRYS) não distribuiu dividendos no último ano.

Is Krystal Biotech (KRYS) a good investment?

Atualmente, Krystal Biotech (KRYS) está cotada a US$ 343.34, com um P/L de 40.87, representando um desvio de 8,621% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 138.5 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 138.50%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Krystal Biotech (KRYS) stock?

Investir em ações de Krystal Biotech (KRYS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Krystal Biotech (KRYS) yield today?

A rentabilidade de Krystal Biotech (KRYS) foi de 1.94% no último mês, 138.50% no último ano e 544.17% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Krystal Biotech (KRYS) hoje, o investimento total seria de US$ 34,334.00, com base na cotação atual de US$ 343.34.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 81,886.59
Em 5 anos: US$ 221,169.33
Em 10 anos: US$ 34,334.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

KRYS

Krystal Biotech Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment KRYS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING KRYS WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Krystal Biotech

Krystal Biotech Inc.

United States

11 years

2017

75

PROFIT X PRICE KRYS

Financial Results KRYS

KRYS cash flow

Asset, Revenue and Profit Growth - KRYS

KRYS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions